Biotech News

Caribou Biosciences to Evaluate Strategic Alternatives

Caribou (CRBU)CaribouCompany update

-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 -- BERKELEY, Calif., Oct.

Related news

Caribou

Genome-Edited Cell Therapy Company Caribou Biosciences applies CRISPR genome editing to create allogeneic cell therapies. Its platform was designed to produce off-the-shelf CAR T candidates with controlled edits intended to improve persistence and antitumor activity. Hematologic Oncology Programs The clinical portfolio included...

Recent company news

Stock data

Close
0.31 USD
Market cap
230.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States